Juliana F Saldanha1, Viviane O Leal2, Felipe Rizzetto3, Gustavo H Grimmer4, Marcelo Ribeiro-Alves5, Julio B Daleprane6, José C Carraro-Eduardo7, Denise Mafra8. 1. Postgraduate Program in Medical Sciences, Federal Fluminense University (UFF), Niterói, Rio de Janeiro, Brazil. Electronic address: jusaldanha@hotmail.com. 2. Postgraduate Program in Cardiovascular Sciences, Federal Fluminense University (UFF), Niterói, Rio de Janeiro, Brazil. 3. Division of Nutrition, Federal Hospital of Lagoa, Rio de Janeiro, Rio de Janeiro, Brazil. 4. Institute of Biophysics, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil. 5. HIV/AIDS Clinical Research Center, National Institute of Infectology, INI, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil. 6. Department of Basic and Experimental Nutrition, Institute of Nutrition, State University of Rio de Janeiro (UERJ), Rio de Janeiro, Rio de Janeiro, Brazil. 7. University Hospital Antonio Pedro, Medicine Faculty of Federal Fluminense University (UFF), Niterói, Rio de Janeiro, Brazil. 8. Postgraduate Program in Medical Sciences, Federal Fluminense University (UFF), Niterói, Rio de Janeiro, Brazil; Postgraduate Program in Cardiovascular Sciences, Federal Fluminense University (UFF), Niterói, Rio de Janeiro, Brazil.
Abstract
INTRODUCTION: Resveratrol is a phenolic compound that has demonstrated anti-inflammatory and antioxidant effects, resulting from enhanced antioxidant enzymes production and modulating nuclear factors involved in the inflammation-oxidative stress cycle, as nuclear erythroid 2-related factor 2 (Nrf2) and nuclear factor-κB (NF-κB). OBJECTIVE: The study aim was to evaluate the effects of resveratrol supplementation on Nrf2 and NF-κB expression in nondialyzed chronic kidney disease (CKD) patients. MATERIALS AND METHODS: A randomized, double-blind, crossover trial was performed in 20 nondialyzed CKD patients (62.0 ± 8.0 years old, 45% men, body mass index of 27.7 ± 1.2 kg/m2, estimated glomerular filtration rate of 34.0 ± 13.0 mL/minute). Eleven patients were randomly allocated to "placebo first" (4 weeks placebo; 8 weeks washout, 4 weeks 500 mg of resveratrol/day) and 9 to "resveratrol first" (4 weeks 500 mg of resveratrol/day, 8 weeks washout, 4 weeks placebo). The peripheral blood mononuclear cells were isolated and processed for expression Nrf2 and NF-κB by quantitative real-time polymerase chain reaction. Proinflammatory cytokines and antioxidant enzymes were also measured. RESULTS: The effect size of Nrf2 supplementation (-0.13, P = .29) and NF-κB (0.09, P = .31) was not significant. There was no difference in proinflammatory biomarkers or antioxidant biomarkers after resveratrol supplementation. CONCLUSION: In this pilot study, 500 mg of resveratrol supplementation for 4 weeks had no antioxidant and anti-inflammatory effect in nondialyzed CKD patients. Additional studies with differing doses and/or time of treatment should be conducted to better elucidate the effects of the resveratrol supplementation in CKD patients.
RCT Entities:
INTRODUCTION:Resveratrol is a phenolic compound that has demonstrated anti-inflammatory and antioxidant effects, resulting from enhanced antioxidant enzymes production and modulating nuclear factors involved in the inflammation-oxidative stress cycle, as nuclear erythroid 2-related factor 2 (Nrf2) and nuclear factor-κB (NF-κB). OBJECTIVE: The study aim was to evaluate the effects of resveratrol supplementation on Nrf2 and NF-κB expression in nondialyzed chronic kidney disease (CKD) patients. MATERIALS AND METHODS: A randomized, double-blind, crossover trial was performed in 20 nondialyzed CKDpatients (62.0 ± 8.0 years old, 45% men, body mass index of 27.7 ± 1.2 kg/m2, estimated glomerular filtration rate of 34.0 ± 13.0 mL/minute). Eleven patients were randomly allocated to "placebo first" (4 weeks placebo; 8 weeks washout, 4 weeks 500 mg of resveratrol/day) and 9 to "resveratrol first" (4 weeks 500 mg of resveratrol/day, 8 weeks washout, 4 weeks placebo). The peripheral blood mononuclear cells were isolated and processed for expression Nrf2 and NF-κB by quantitative real-time polymerase chain reaction. Proinflammatory cytokines and antioxidant enzymes were also measured. RESULTS: The effect size of Nrf2 supplementation (-0.13, P = .29) and NF-κB (0.09, P = .31) was not significant. There was no difference in proinflammatory biomarkers or antioxidant biomarkers after resveratrol supplementation. CONCLUSION: In this pilot study, 500 mg of resveratrol supplementation for 4 weeks had no antioxidant and anti-inflammatory effect in nondialyzed CKDpatients. Additional studies with differing doses and/or time of treatment should be conducted to better elucidate the effects of the resveratrol supplementation in CKDpatients.
Authors: Isabelle C V S Martins; Natália A Borges; Peter Stenvinkel; Bengt Lindholm; Hervé Rogez; Maria C N Pinheiro; José L M Nascimento; Denise Mafra Journal: Int Urol Nephrol Date: 2018-06-18 Impact factor: 2.370
Authors: Carmela Cosola; Maria Teresa Rocchetti; Ighli di Bari; Paola Maria Acquaviva; Valentina Maranzano; Simone Corciulo; Agostino Di Ciaula; Domenica Maria Di Palo; Flavia Maria La Forgia; Sergio Fontana; Maria De Angelis; Piero Portincasa; Loreto Gesualdo Journal: Toxins (Basel) Date: 2021-05-05 Impact factor: 4.546